MALACTRES

"Multi-drug resistance in malaria under combination therapy: Assessment of specific markers and development of innovative, rapid and simple diagnostics."

 Coordinatore HET KONINKLIJK INSTITUUT VOOR DE TROPEN 

 Organization address address: "Mauritskade, 63"
city: AMSTERDAM
postcode: 1092 AD

contact info
Titolo: Dr.
Nome: Hendricus
Cognome: Schallig
Email: send email
Telefono: +31 20 5665447
Fax: +31 20 6971841

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 3˙738˙056 €
 EC contributo 2˙800˙358 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-01-01   -   2013-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    HET KONINKLIJK INSTITUUT VOOR DE TROPEN

 Organization address address: "Mauritskade, 63"
city: AMSTERDAM
postcode: 1092 AD

contact info
Titolo: Dr.
Nome: Hendricus
Cognome: Schallig
Email: send email
Telefono: +31 20 5665447
Fax: +31 20 6971841

NL (AMSTERDAM) coordinator 0.00
2    CENTRE MURAZ

 Organization address address: Avenue Mamadou Konate
city: BOBO-DIOULASSO
postcode: NA

contact info
Titolo: Mr.
Nome: Amadou Saoud
Cognome: Sonde
Email: send email
Telefono: +226 20974222
Fax: +226 20970457

BF (BOBO-DIOULASSO) participant 0.00
3    FORSITE DIAGNOSTICS LTD

 Organization address address: BLOCK 21, Sand Hutton
city: YORK
postcode: YO41 1LZ

contact info
Titolo: Mr.
Nome: Christopher
Cognome: Danks
Email: send email
Telefono: +44 1904 462331
Fax: +44 1904 462122

UK (YORK) participant 0.00
4    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

 Organization address address: KEPPEL STREET
city: LONDON
postcode: WC1E7HT

contact info
Titolo: Mr.
Nome: Chris
Cognome: Andrews
Email: send email
Telefono: +44 20 79272486
Fax: +44 20 75805636

UK (LONDON) participant 0.00
5    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE

 Organization address address: Nationalestraat 155
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Mr.
Nome: Jef
Cognome: Van Lint
Email: send email
Telefono: +32 3 2476486
Fax: +32 3 2476223

BE (ANTWERPEN) participant 0.00
6    STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK

 Organization address address: Costerweg 50
city: WAGENINGEN
postcode: 6701BH

contact info
Titolo: Mr.
Nome: Erik
Cognome: Westerhof
Email: send email
Telefono: +31 317 475009

NL (WAGENINGEN) participant 0.00
7    THE GOOD SAMARITAN FOUNDATION (KILIMANJARO CHRISTIAN MEDICAL CENTRE GSF KCMC)

 Organization address address: KILIMANJARO CHRISTIAN MEDICAL CENTRE
city: MOSHI
postcode: -

contact info
Titolo: Dr.
Nome: Jan Teun
Cognome: Bousema
Email: send email
Telefono: +255 782390707
Fax: +255 272754381

TZ (MOSHI) participant 0.00
8    UNIVERSITY OF BENIN*

 Organization address address: TROPICAL DISEASES RESEARCH GROUP FACULTY OF PHARMACY UNIVERSITY OF BENIN
city: BENIN CITY
postcode: 300001

contact info
Titolo: Dr.
Nome: Ehijie
Cognome: Enato
Email: send email
Telefono: +234 8023597448
Fax: +234 52 602370

NG (BENIN CITY) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

markers    sensitivity    endpoints    mosquitoes    act    parasites    candidate    detection    patients    alleles    individuals    trials    commercial    clinical    gametocyte    falciparum    rapid    drug    treated    simple    validate    tech    diagnostic       impact    transmission    resistance    genetic    vitro    treatment    tests   

 Obiettivo del progetto (Objective)

'This project aims to assess specific P. falciparum genetic markers for resistance to artemisinin-based combinations (ACT), and to develop innovative, rapid and simple diagnostics for malaria and these markers. Specific objectives are: • To develop and evaluate in disease endemic countries accurate low-tech molecular diagnostic tests. • To identify alleles of candidate resistance genes associated with increased transmission success of P. falciparum after ACT treatment in completed clinical trials (endpoints at gametocyte or infected mosquito level). • To conduct ACT treatment trials with transmission endpoints, and measure impact of resistance-associated alleles on gametocyte emergence, and on the infectiousness of gametocyte-positive or randomly-selected treated individuals to Anopheles mosquitoes. • To measure ACT efficacy using in vivo treatment trials, and in vitro drug sensitivity testing of natural parasite isolates. The impact of candidate resistance markers will be measured in patients with treatment failure, and in parasites with reduced in vitro sensitivity. • To develop new low-tech diagnostic tools able to demonstrate the presence of mutations conferring drug resistance in the Plasmodium population, particularly those markers validated by the project. • To investigate commercial value aspects of developed tests. The project will move our knowledge of ACT resistance forward in 2 complementary ways: 1) In order to identify and validate genetic markers for ACT resistance, we will use our unprecedented access to parasites isolated both from ACT-treated individuals and from mosquitoes fed on blood from ACT-treated individuals. 2) we will develop and validate simple tests in new formats for detection of these and other markers of relevance, and for rapid detection of persisting parasites in treated patients. The work is a balanced mix of clinical field work, laboratory research and (commercial) test development and linked to EU initiative EDCTP.'

Altri progetti dello stesso programma (FP7-HEALTH)

BRAINTRAIN (2013)

Taking imaging into the therapeutic domain: Self-regulation of brain systems for mental disorders

Read More  

CARING (2011)

CAncer Risk and INsulin analoGues

Read More  

PROACTIVE (2008)

High Throughput Proteomics Systems for Accelerated Profiling of Putative Plasma Biomarkers

Read More